Collectively, these findings identify the HK1–glycolysis–NLRP3 axis as a critical metabolic–inflammatory link in CKD-related vascular calcification and suggest that Irisin/HK1 targeting may represent a promising therapeutic strategy to disrupt pyroptosis-driven vascular injury in CKD. This evidence concerns the gene HK1 and chronic kidney disease.